Sen­si­tized by a se­ries of scan­dals around the world, No­var­tis spot­lights its ethics poli­cies

It turns out that any­one who doesn’t main­tain the ethics stan­dards at a new­ly sen­si­tized No­var­tis has run the risk of los­ing a bonus.

Taint­ed by a po­lit­i­cal scan­dal in Wash­ing­ton DC trig­gered by a con­tract signed by ex-CEO Joe Jimenez, the com­pa­ny de­cid­ed to talk up a scor­ing sys­tem it adopt­ed in 2016 where each staffer earns a 1, 2 or 3 num­ber rank­ing on ethics. Two qual­i­fies as meet­ing com­pa­ny ethics stan­dards and 3 qual­i­fies for role mod­el be­hav­ior — all of which could sig­nal the kind of per­for­mance war­rant­i­ng up to 35% of their to­tal com­pen­sa­tion, ac­cord­ing to a re­port from Reuters, which got briefed with an­a­lysts and re­porters on the pro­gram.

(I’m still wait­ing for my in­vi­ta­tion to that club.)

Shan­non Klinger

The Co­hen scan­dal, in­volv­ing No­var­tis’ pay­ment of $1.2 mil­lion to Trump’s per­son­al at­tor­ney Michael Co­hen, took place af­ter oth­er scan­dals in Chi­na, South Ko­rea and Greece. In Chi­na, com­pa­ny ex­ecs re­port­ed­ly start­ed a pi­lot project where ex­pense re­ports are scru­ti­nized in a move to get ahead of any oth­er rep­u­ta­tion dam­ag­ing be­hav­ior.

“This al­lows us to look at the be­hav­ior met­ric be­fore any mon­ey leaves No­var­tis, and catch po­ten­tial mis­con­duct be­fore there is any risk to our rep­u­ta­tion,” said No­var­tis gen­er­al coun­sel Shan­non Klinger, ac­cord­ing to the Reuters re­port.

Iron­i­cal­ly, Klinger had been the ethics czar at No­var­tis be­fore the scan­dal hit. She re­placed chief at­tor­ney Fe­lix Ehrat, who left abrupt­ly af­ter the lurid head­lines hit about Michael Co­hen, say­ing their con­tract was le­gal but a mis­take.

Vas Narasimhan

That’s the same ap­proach tak­en by new CEO Vas Narasimhan, who’s been try­ing to dis­tance him­self as much as pos­si­ble from any­thing hav­ing to do with this scorch­ing event. The com­pa­ny in­sists that the con­nec­tion with Co­hen was brief and un­pro­duc­tive, a po­si­tion ridiculed by De­mo­c­ra­t­ic sen­a­tors who say there was a long trail of com­mu­ni­ca­tions be­tween Co­hen and ex-CEO Jimenez. 

As for Jimenez, who was as­signed the bulk of the blame for de­cid­ing to en­ter in­to a con­tract with Co­hen and pay the whole thing off? Com­pa­ny fil­ings show that he earned more than $11.3 mil­lion in com­pen­sa­tion for 2017.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

An increase in demand of up to 79% for clinical trials in China has prompted Novotech the Asia-Pacific CRO to rapidly expand the China team, appointing expert local clinical executives to their Shanghai and Hong Kong offices. The company is planning to expand their team by 30% over the next quarter.

Novotech China has seen considerable demand recently which is borne out by research from GlobalData:
A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world, with growth as high as 79% in China.
Novotech CEO Dr John Moller said China offers the largest population in the world, rapid economic growth, and an increasing willingness by government to invest in research and development.
Novotech’s 23 years of experience working in the region means we are the ideal CRO partner for USA biotechs wanting to tap the research expertise and opportunities that China offers.
There are over 22,000 active investigators in Greater China, with about 5,000 investigators with experience on at least 3 studies (source GlobalData).

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.

Den­mark's Gen­mab hits the jack­pot with $500M+ US IPO as small­er biotechs rake in a com­bined $147M

Danish drugmaker Genmab A/S is off to the races with perhaps one of the biggest biotech public listings in decades, having reaped over $500 million on the Nasdaq, as it positions itself as a bonafide player in antibody-based cancer therapies.

The company, which has long served as J&J’s $JNJ key partner on the blockbuster multiple myeloma therapy Darzalex, has asserted it has been looking to launch its own proprietary product — one it owns at least half of — by 2025.

FDA over­rides ad­comm opin­ions a fifth of the time, study finds — but why?

For drugmakers, FDA advisory panels are often an apprehended barometer of regulators’ final decisions. While the experts’ endorsement or criticism often translate directly to final outcomes, the FDA sometimes stun observers by diverging from recommendations.

A new paper out of Milbank Quarterly put a number on that trend by analyzing 376 voting meetings and subsequent actions from 2008 through 2015, confirming the general impression that regulators tend to agree with the adcomms most of the time — with discordances in only 22% of the cases.

UP­DAT­ED: With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

Merck — one of the last large biopharmaceuticals companies in the beleaguered field of antibiotic drug development — on Wednesday said the FDA had sanctioned the approval of its combination antibacterial for the treatment of complicated urinary tract and intra-abdominal infections.

To curb the rise of drug-resistant bacteria and maintain the efficacy of the therapy, Recarbrio (and other antibacterials) — the drug must be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible gram-negative bacteria, Merck $MRK said.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.